Celebrating 25 Years of Scoop
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register PHARMAC for InfoPages here.
PHARMAC - Latest News [Page 3]
Pharmac Considers Access Criteria For COVID-19 Antiviral Treatments
Tuesday, 1 August 2023, 2:58 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is consulting on changes to the access criteria for all COVID-19 antiviral treatments to include more people who are at risk of becoming severely ill from the infection. “We now know that these antiviral treatments can ... More >>
Pharmac Joins International Collaboration To Advance Use Of Health Technology Assessments
Thursday, 20 July 2023, 1:05 pm | PHARMAC
Pharmac has joined an international collaboration of government health technology assessment (HTA) agencies. Together with partners from Australia, the United Kingdom and Canada we're working to make health systems better by sharing HTA knowledge and ... More >>
Pharmac Seeking Bids From Suppliers For Continuous Glucose Monitors, Insulin Pumps And Consumables
Tuesday, 11 July 2023, 11:10 am | PHARMAC
Te Pātaka Whaioranga - Pharmac is seeking commercial bids from suppliers for the supply of funded continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables for people living with type 1 diabetes. “We are really pleased to be ... More >>
Pharmac Considers Widening Access To Treatments For Multiple Sclerosis And Haemophilia A
Thursday, 22 June 2023, 3:35 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) ... More >>
Pharmac Seeks Feedback On Widening Access And Transitioning To A Biosimilar Trastuzumab
Thursday, 8 June 2023, 2:10 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is considering awarding Principal Supply to a biosimilar brand of trastuzumab (branded as Herzuma), and widening access to include those with stomach (gastric) cancer, from 1 December 2023. Consultation on the proposal ... More >>
Pharmac Funds Second Treatment For Spinal Muscular Atrophy
Tuesday, 11 April 2023, 1:46 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac has announced the funding of risdiplam (branded as Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet eligibility criteria from 1 May 2023. “We’re pleased to announce that we ... More >>
Pharmac Shares Next Steps In Reviewing Rule 8.1b
Wednesday, 5 April 2023, 11:06 am | PHARMAC
Te Pātaka Whaioranga – Pharmac’s consultation on rule 8.1b of the Pharmaceutical Schedule has now closed. “Rule 8.1b is a unique exception that means any medicine used to treat cancer in a paediatric setting is automatically funded without a Pharmac ... More >>
Pharmac Seeking Feedback On The COVID-19 Antiviral Molnupiravir
Tuesday, 4 April 2023, 11:58 am | PHARMAC
Te Pātaka Whaioranga – Pharmac are consulting on the role of molnupiravir in New Zealand’s portfolio of COVID-19 treatments. The consultation seeks feedback on whether Pharmac should stop funding the treatment or adjust the eligibility criteria ... More >>
Pharmac Considers Funding Rituximab For IgG4-related Disease
Thursday, 23 March 2023, 10:05 am | PHARMAC
Te Pātaka Whaioranga - Pharmac has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for people with IgG4-related disease, a chronic inflammatory condition. “Pharmac currently funds rituximab for several ... More >>
Pharmac Funds Two New Treatments For Lung Cancer
Tuesday, 7 March 2023, 12:10 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac has announced the funding of two new medicines - pembrolizumab (branded as Keytruda) and atezolizumab (branded as Tecentriq) for people with locally advanced and metastatic non-small cell lung cancer who meet certain ... More >>
Pharmac Announces Decision To Fund Trikafta
Tuesday, 7 March 2023, 12:02 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac has today confirmed the funding of elexacaftor with tezacaftor and ivacaftor (branded as Trikafta) for people with cystic fibrosis, aged 6 years and above, who meet certain eligibility criteria. “We’re thrilled ... More >>
Pharmac Releases Final Response To Review
Friday, 3 March 2023, 12:19 pm | PHARMAC
Today, we are releasing our final response to the Pharmac review. “The independent Review of Pharmac was an opportunity for us to reflect on what we do, how we do it, and where we can make improvements for the benefit of all New Zealanders,” ... More >>
Pharmac Confirms Widened Access To The Funded Flu Vaccine
Thursday, 2 March 2023, 12:14 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is widening access to the annual funded flu vaccine to tamariki aged 6 months to 12 years and will again offer it to Māori and Pacific peoples who are 55 to 64 years of age for the 2023 flu season. “The flu vaccine ... More >>
Pharmac Shares Agenda Items For The Upcoming Rare Disorders Committee Meeting
Monday, 27 February 2023, 1:36 pm | PHARMAC
Te Pātaka Whaioranga – Pharmac is creating visibility of what medicines are being considered that could impact the rare disorders community by sharing the agenda items for the upcoming Rare Disorders Advisory Committee meeting. Pharmac’s Chief Medical ... More >>
Pharmac Proposing To Phase Out Food Thickeners
Wednesday, 22 February 2023, 1:00 pm | PHARMAC
Today Te Pātaka Whaioranga - Pharmac is beginning a consultation to better understand how phasing out the funding of food thickeners in the community would affect people who use them. Pharmac’s chief medical officer Dr David Hughes says, “Food thickeners ... More >>
Pharmac Signals First Step Towards Funding Continuous Glucose Monitors
Tuesday, 21 February 2023, 12:11 pm | PHARMAC
Te Pātaka Whaioranga - Pharmac will soon be seeking competitive commercial offers for the supply of funded Continuous Glucose Monitors (CGMs) in New Zealand. “Today we have issued a Future Procurement Opportunity for CGMs, insulin pumps, and insulin ... More >>
Pharmac Seeking Feedback On Funding A Second SMA Treatment
Thursday, 19 January 2023, 7:45 am | PHARMAC
Te Pātaka Whaioranga - Pharmac is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (branded as Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet the eligibility criteria. Pharmac’s ... More >>
Pharmac Funds More Treatments For People With Inflammatory Bowel Disease
Tuesday, 20 December 2022, 5:16 am | PHARMAC
20 December 2022 Te Pātaka Whaioranga - Pharmac has today announced funding of ustekinumab (branded as Stelara) for people with inflammatory bowel disease (IBD) and the widening of funded access to infliximab (branded as Remicade) for people ... More >>
Pharmac Consulting On Two New Medicines For Lung Cancer
Friday, 16 December 2022, 9:01 am | PHARMAC
Te Pātaka Whaioranga – Pharmac has reached provisional agreements with two different suppliers to fund two medicines to treat New Zealanders with advanced non-small cell lung cancer. The medicines are pembrolizumab (brand name Keytruda) and atezolizumab ... More >>
Pharmac To Fund The EpiPen For Severe Allergies
Thursday, 15 December 2022, 5:22 am | PHARMAC
Te Pātaka Whaioranga - Pharmac has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto injectors from 1 February 2023, which will benefit thousands of New Zealanders. “We are pleased to be able to share that adrenaline ... More >>
